Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 54

Ionis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides

The European Commission cleared Ionis' Tryngolza (olezarsen) for adults with severe hypertriglyceridemia and fasting triglycerides of at least 880 mg/dL, making it the first RNA-targeted therapy approved for that group in the EU. The win follows a positive CHMP opinion in October 2026, but it lands as US sales of the drug badly miss expectations and Ionis' stock sinks 65.9% this year.

By the Paparazzi desk November 18, 2026 · 8:34 AM · finance.yahoo.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 18, 2026 at 8:34 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The European Commission has signed off on Tryngolza for adults with severe hypertriglyceridemia whose fasting triglyceride levels hit at least 880 mg/dL. Patients will take the olezarsen-based drug alongside diet and other lipid-lowering therapies. It is the first RNA-targeted therapy cleared in the European Union for this patient population.

The green light was no surprise. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval back in October 2026, and Ionis already held an EU nod for familial chylomicronemia syndrome from 2025. This decision stretches the label to a much wider group. The FDA had cleared Tryngolza for sHTG in the US in June 2026.

Sponsored

The European filing leaned on the phase III CORE and CORE2 trials, which both hit their primary endpoints with significant drops in fasting triglycerides versus placebo. The studies also showed fewer acute pancreatitis events and a favorable safety and tolerability profile. That matters because triglycerides at or above 880 mg/dL carry a higher risk of acute pancreatitis, a life-threatening condition that can bring severe abdominal pain, long hospital stays and permanent organ damage. For context, sHTG itself starts at 500 mg/dL.

Sobi holds exclusive commercialization rights to Tryngolza outside the United States, Canada and China, so the EU expansion widens the drug's reach without Ionis building its own European sales force. Ionis sells it directly in the US, where it is the company's first wholly owned commercial product, first approved by the FDA for FCS in December 2024.

The commercial picture is grimmer than the regulatory one. Tryngolza posted $41 million in net product sales over the first nine months of 2026, down 28.5% year over year, and roughly $9 million in the third quarter alone, missing the Zacks Consensus Estimate of $23.1 million. Management blamed a slower-than-expected launch ramp, with physicians taking time to adopt the treatment and reimbursement coverage filling in gradually. Ionis cut its full-year 2026 Tryngolza sales guidance from $100-$110 million to about $50 million. Shares of IONS have fallen 65.9% so far this year, against a 1.8% drop for the industry.

TopicsIonis Pharmaceuticals · Tryngolza · olezarsen · European Commission · Sobi · IONS · FDA · European Medicines Agency

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 18:16 UTC · 3 hours ago · theguardian.com · 0 views
    E coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
  • Health & science 17:31 UTC · 3 hours ago · rarecancernews.com · 2 views
    EU approves Rasonque for previously treated metastatic pancreatic cancer
  • Health & science 16:53 UTC · 4 hours ago · medicalxpress.com · Caught by @breakwater128 · 2 views
    Five-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds
  • Health & science 15:47 UTC · 5 hours ago · dailycoffeenews.com · 2 views
    FDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.